MEDICAL devices company Calcivis has been accepted into the next cohort of the London Stock Exchange (LSE)’s Elite programme that supports ambitious companies towards growth and investment.

Edinburgh based Calcivis focuses on the management of tooth decay and enabling preventive dentistry. Its chief executive officer, Adam Christie, said: “This is a significant achievement… We are excited about this programme which will provide us with support as we embark on the next phase of our growth including launch of the [cavity prevention device] Calcivis System in the UK market next year, together with a premarket authorisation filing to FDA in advance of marketing in the US.”

The Elite programme will facilitate structured engagement between Calcivis, entrepreneurs and business leaders, as well as the corporate advisory and investor community, through a package of education, business support and access to investors.